PTEN (Phosphatase and Tensin Homolog on chromosome TEN) encodes a vastly expressed tumor suppressor protein that antagonizes the PI3 K signaling pathway and alters the MTOR pathway. Mutations in PTEN have been described in association with a number of syndromes including PTEN hamartoma-tumor syndrome, macrocephaly/autism, and juvenile polyposis of infancy. Although there is a wide variability in the clinical and radiologic presentations of PTEN-related phenotypes, the most consistent features include macrocephaly and increased tumorigenesis. Intracranial hypertension may be idiopathic or secondary to multiple etiologies. We describe 2 siblings harboring a PTEN mutation who presented with macrocephaly and intracranial hypertension. Repeat brain MRIs were normal in both. Acetazolamide treatment normalized intracranial pressure, but several trials of medication tapering led to recurrence of intracranial hypertension symptoms. The clinical presentation of our patients expands the PTEN-related phenotypes. We discuss the possible pathophysiology in view of PTEN function.
LiJYenCLiawD. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–1947.
2.
PezzolesiMGZbukKMWaiteKAEngC. Comparative genomic and functional analyses reveal a novel cis-acting PTEN regulatory element as a highly conserved functional E-box motif deleted in Cowden syndrome. Hum Mol Genet. 2007;16:1058–1071.
3.
ChuECTarnawskiAS. PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit. 2004;10:RA235–RA241.
4.
EngC. PTEN hamartoma tumor syndrome. In: AdamMPArdingerHHPagonRA, eds. GeneReviewsÒ. Seattle, WA: University of Washington; 1993.
5.
MollanSPAliFHassan-SmithGBotfieldHFriedmanDISinclairAJ. Evolving evidence in adult idiopathic intracranial hypertension: pathophysiology and management. J Neurol Neurosurg Psychiatry. 2016;87:982–992.
6.
BalcerLJLiuGTFormanS. Idiopathic intracranial hypertension: relation of age and obesity in children. Neurology. 1999;52:870–872.
GeniziJLahatEZelnikNMahajnahMRavidSShaharE. Childhood-onset idiopathic intracranial hypertension: relation of sex and obesity. Pediatr Neurol. 2007;36:247–249.
11.
GiridharanNPatelSKOjugbeliA. Understanding the complex pathophysiology of idiopathic intracranial hypertension and the evolving role of venous sinus stenting: a comprehensive review of the literature. Neurosurg Focus. 2018;45:E10.
12.
BuellTJStarkeRMDingD. Venous sinus stenting using transcranial access for the treatment of idiopathic intracranial hypertension in a pediatric patient. J Neurosci Rural Pract. 2017;8:672–675.
ElderBDGoodwinCRKosztowskiTA. Venous sinus stenting is a valuable treatment for fulminant idiopathic intracranial hypertension. J Clin Neurosci. 2015;22:685–689.
26.
AracALeeMSteinbergGKMarcellusMMarksMP. Efficacy of endovascular stenting in dural venous sinus stenosis for the treatment of idiopathic intracranial hypertension. Neurosurg Focus. 2009;27:E14.
27.
KaramanKGverovic-AntunicaAZuljanI. Familial idiopathic intracranial hypertension. Croat Med J. 2003;44:480–484.
28.
TorlaiFGalassiGDebbiaACrisiGPeduzziM. Familial pseudotumor cerebri in male heterozygous twins. Eur Neurol. 1989;29:106–108.
GardnerKCoxTDigreKB. Idiopathic intracranial hypertension associated with tetracycline use in fraternal twins: case reports and review. Neurology. 1995;45:6–10.
31.
CoffeyCERossDRMasseyEWOlanowCW. Familial benign intracranial hypertension and depression. Can J Neurol Sci. 1982;9:45–47.
32.
SantinelliRToloneCToraldoRCaninoGDe SimoneAD’AvanzoM. Familial idiopathic intracranial hypertension with spinal and radicular pain. Arch Neurol. 1998;55:854–856.
33.
PeltierJLokCFichtenA. Lhermitte-Duclos disease and Cowden’s syndrome. Report of two cases. Neurochirurgie. 2006;52:407–414.
34.
MarshDJCoulonVLunettaKL. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet. 1998;7:507–515.
MarzbanANSaxenaABhattacharyyaDIvanovM. Hydrocephalus and papilledema in spinal cord tumors: a report of two cases. Surg J (N Y). 2016;2:e51–e58.
37.
TrevisiGFrassanitoPDi RoccoC. Idiopathic cerebrospinal fluid overproduction: case-based review of the pathophysiological mechanism implied in the cerebrospinal fluid production. Croat Med J. 2014;55:377–387.
TanWHBarisHNBurrowsPE. The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management. J Med Genet. 2007;44:594–602.
40.
DimmelerSFlemingIFisslthalerBHermannCBusseRZeiherAM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601–605.
41.
MichellBJGriffithsJEMitchelhillKI. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr Biol. 1999;9:845–848.
42.
SampaioWOSouza dos SantosRAFaria-SilvaRda Mata MachadoLTSchiffrinELTouyzRM. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension. 2007;49:185–192.
43.
Rangel-CastillaLGopinathSRobertsonCS. Management of intracranial hypertension. Neurol Clin. 2008;26:521–541, x.
44.
Parness-YossifonRMargalitDPollackALeibaH. Behavioral disorders in children with idiopathic intracranial hypertension. J Child Neurol. 2008;23:447–450.
45.
WeigSG. Asymptomatic idiopathic intracranial hypertension in young children. J Child Neurol. 2002;17:239–241.
